Aptose Biosciences is biotechnology company developing agents to treat medical needs in cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Co.'s product pipeline includes cancer drug candidates that exert potent activity as stand-alone agents and that improve the activities of other anticancer agents without causing overlapping toxicities. Co.'s clinical-stage programs include: CG-806, which is a mutation-agnostic FMS-like tyrosine kinase 3 / Bruton's tyrosine kinase inhibitor; and APTO-253, which is a small molecule MYC oncogene inhibitor. The APTO average annual return since 2014 is shown above.
The Average Annual Return on the APTO average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether APTO average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the APTO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|